Every material Form 8-K Acurx Pharmaceuticals, Inc. has filed with the SEC since July 31, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Acurx Pharmaceuticals agreed on April 15, 2026 to sell about $2.5 million of common stock and pre-funded warrants in a registered direct offering at $3.03 per share, before placement agent fees and expenses. A concurrent private placement adds Series H warrants for 1,650,170 shares at $2.78 per share, which could bring up to about $4.6 million if fully exercised, so existing shareholders face dilution and the warrants are not assured to be exercised.
Registered offering: 816,068 common shares at $3.03 per share, plus pre-funded warrants for 9,017 shares at $3.029, for about $2.5 million gross before fees
Concurrent private placement: Series H warrants for 1,650,170 shares at $2.78 per share, exercisable immediately and expiring 24 months after the resale registration becomes effective
Placement agent H.C. Wainwright & Co. receives a cash fee of 6.0% of gross proceeds, plus up to $50,000 for legal fees and $15,950 for clearing expenses
Closing is expected on or about April 16, 2026; the company plans to use proceeds for working capital and general corporate purposes
Acurx Pharmaceuticals said executive officers voluntarily agreed to base salary reductions of 10%, effective April 1, 2026, and the board approved a 10% cut to the cash components of non-employee director pay. The company also announced a pilot trial of its lead antibiotic candidate, ibezapolstat, in patients with multiply-recurrent C. difficile infection, with trial start-up later in March and first-patient enrollment expected in the fourth quarter of 2026, subject to appropriate funding.
CEO David P. Luci and Executive Chairman Robert J. DeLuccia will each have a $495,000 annual base salary, and CFO Robert G. Shawah will have $360,000, effective April 1, 2026
Director cash compensation, including board, chair and committee retainers, will be reduced by 10% effective April 1, 2026
The open-label pilot trial will enroll up to 20 patients who have had at least two recurrences within the past 12 months; data will inform a planned Phase 3 trial
Acurx Pharmaceuticals filed a certificate of amendment to combine every twenty shares of its common stock into one share, effective 4:01 p.m. Eastern Time on August 4, 2025. The company says the split is intended to raise the per-share trading price so it can regain compliance with Nasdaq's minimum bid price requirement. Shareholders will receive cash in lieu of any fractional shares, and the number of authorized shares will not change.
Ratio is 1-for-20, with shares expected to trade on a split-adjusted basis on The Nasdaq Capital Market from August 5, 2025 under the symbol ACXP
Shares outstanding are expected to fall from about 30,764,540 as of July 24, 2025 to about 1,538,227 after the split
Stockholders approved the reverse split at the annual meeting held July 17, 2025
The stated purpose is to help the company regain compliance with Nasdaq's minimum bid price requirement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Acurx Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →